2. Coker OO, Nakatsu G, Dai RZ, Wu WKK, Wong SH, Ng SC, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut. 2019;68(4):654-662.
https://doi.org/10.1136/gutjnl-2018-317178.
3. Kaźmierczak-Siedlecka K, Dvořák A, Folwarski M, Daca A, Przewłócka K, Makarewicz W. Fungal gut microbiota dysbiosis and its role in colorectal, oral, and pancreatic carcinogenesis. Cancers (Basel). 2020;12(5):1326.
https://doi.org/10.3390/cancers12051326.
4. Tubino PV, Sarmento BJ, dos Santos VM, Borges ER, da Silva LE, Lima Rde S. Synchronous oral paracoccidioidomycosis and esophageal carcinoma. Mycopathologia. 2012;174(2):157-161.
https://doi.org/10.1007/s11046-012-9527-x.
5. Vallianou N, Kounatidis D, Christodoulatos GS, Panagopoulos F, Karampela I, Dalamaga M. Mycobiome and cancer: what is the evidence? Cancers (Basel). 2021;13(13):3149.
https://doi.org/10.3390/cancers13133149.
6. Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706.
https://doi.org/10.1136/gutjnl-2020-323020.
7. Yuan X, Chang C, Chen X, Li K. Emerging trends and focus of human gastrointestinal microbiome research from 2010-2021: a visualized study. J Transl Med. 2021;19(1):327.
https://doi.org/10.1186/s12967-021-03009-8.
9. Zhang S, Kong C, Yang Y, Cai S, Li X, Cai G, et al. Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer. Theranostics. 2020;10(25):11595-11606.
https://doi.org/10.7150/thno.49515.